ESC 365 - Managing patients with heart failure and coronary artery disease: where are we now?

ESC Premium Access

Managing patients with heart failure and coronary artery disease: where are we now?

Session: New directions in the management of thrombotic risks in patients with heart failure

Topic: Treatment

Speaker: Professor D. van Veldhuisen (Groningen, NL)

Sponsored by Bayer AG

Event: ESC Congress 2018

Congress Presentation

About the speaker

Professor Dirk van Veldhuisen

University Medical Centre Groningen, Groningen (Netherlands (The))

20 presentations

0 follower

5 more presentations in this session

Opening remarks - New directions in the management of thrombotic risks in patients with heart failure.

Speaker: Professor F. Zannad (Vandoeuvre-Les-Nancy, FR)

Rivaroxaban in heart failure and conorary artery disease: the COMMANDER-HF study.

The new data in context: clinical implications for patients with heart failure.

The new data in context: future perspectives for patients with heart failure.

Speaker: Professor B. Pieske (Berlin, DE)

Closing remarks - New directions in the management of thrombotic risks in patients with heart failure.

Speaker: Professor F. Zannad (Vandoeuvre-Les-Nancy, FR)

Access the full session

New directions in the management of thrombotic risks in patients with heart failure

Speakers: Professor D. van Veldhuisen, Professor F. Zannad, Professor B. Pieske, Professor F. Zannad

About the event

ESC Congress 2018

7 November - 29 August 2018

Sessions Presentations

Congress

ESC 365 is supported by